-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Biomedicine is one of the strategic emerging industries with great promise and prospect.
Since the beginning of this year, relevant state departments have issued the "14th Five-Year Plan for Pharmaceutical Industry Development" and the "14th Five-Year Plan" for Biomedicine The Economic Development Plan and many other documents point out the direction for the future high-quality development of the biopharmaceutical industr.
At present, under the guidance of these documents, many places have also begun to seize the opportunity of great industrial developmen.
On the basis of giving full play to local advantages, they have continuously issued favorable documents to accelerate the promotion of high-end, large-scale, and high-end biomedicine and new medical equipment industrie.
Intensive developmen.
Shanghai At present, Shanghai is accelerating the creation of a biopharmaceutical industry innovation highland with global influence and a world-class biopharmaceutical industry cluster, striving to exceed one trillion yuan by 2025.As a part of the "Shanghai Pharmaceuticals" industry map, Fengxian District of Shanghai is moving towards an important carrier of the world-class biopharmaceutical industry cluste.
It is reported that Li Zheng, secretary of the Fengxian District Party Committee, said at a seminar on the high-quality development of the biomedical industry in the Yangtze River Delta on August 11 that in recent years, Fengxian District has made every effort to launch the "Oriental Beauty Valley" brand and vigorously develop the beauty, health and biomedical industrie.
Up to now, Fengxian District has gathered more than 200 biopharmaceutical companies and introduced a number of functional platform.
Fengxian District will strive to become an important carrier for Shanghai to build a world-class biopharmaceutical industry cluste.
Hainan Hainan has always regarded the biopharmaceutical industry as one of the leading industries, and the "14th Five-Year Plan for the Development of High-tech Industries in Hainan Province" lists modern biopharmaceuticals as a strategic emerging industr.
It is worth mentioning that among them, Haikou has begun to build a 100 billion-level high-end pharmaceutical and medical device industry cluste.
At the same time, favorable policies are also being introduce.
On July 12, Haikou released the "Yecheng Talent Plan" focusing on key industries, including 35 measures such as full-cycle talent incentives and building a scientific research and innovation platform, to cultivate talents for industrial transformatio.
According to reports, in the next step, Haikou will introduce more flexible and precise support policies, build more platforms for cooperation and exchange, pay close attention to enterprise service guarantees, form an efficient and coordinated development of innovation chains and industrial chains, and support high-end, large-scale and intensive biopharmaceutical industrie.
developmen.
Shenzhen In recent years, Shenzhen has also highly supported the development of the biopharmaceutical industry, and favorable policies have continued this yea.
For example, in June, the "Shenzhen Action Plan for Cultivating and Developing Biomedical Industry Clusters (2022-2025)", "Shenzhen's Action Plan for Cultivating and Developing High-end Medical Device Industry Clusters (2022-2025)", "Shenzhen Cultivation and Development of High-end Medical Device Industry Clusters (2022-2025)" Health Industry Cluster Action Plan (2022-2025)" and other document.
In July, "Several Measures for Shenzhen to Promote the High-quality Development of Biomedical Industry Clusters", "Several Measures for Shenzhen to Promote the High-quality Development of High-end Medical Device Industry Clusters" and "Shenzhen's Measures for Promoting the High-quality Development of Big Health Industry Clusters" were successively release.
"Several Measures" and other policies to support Shenzhen to expand and strengthen the biomedical industr.
Conclusion Judging from the current intensive moves to support the high-quality and innovative development of the biopharmaceutical industry, the industry expects that the biopharmaceutical industry will enter the "fast lane" and will accelerate the realization of the "14th Five-Year Plan for the Development of the Biopharmaceutical Industry" It is proposed that by 2025, the operating income of the biopharmaceutical industry will reach 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth rate of more than 10.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
Since the beginning of this year, relevant state departments have issued the "14th Five-Year Plan for Pharmaceutical Industry Development" and the "14th Five-Year Plan" for Biomedicine The Economic Development Plan and many other documents point out the direction for the future high-quality development of the biopharmaceutical industr.
At present, under the guidance of these documents, many places have also begun to seize the opportunity of great industrial developmen.
On the basis of giving full play to local advantages, they have continuously issued favorable documents to accelerate the promotion of high-end, large-scale, and high-end biomedicine and new medical equipment industrie.
Intensive developmen.
Shanghai At present, Shanghai is accelerating the creation of a biopharmaceutical industry innovation highland with global influence and a world-class biopharmaceutical industry cluster, striving to exceed one trillion yuan by 2025.As a part of the "Shanghai Pharmaceuticals" industry map, Fengxian District of Shanghai is moving towards an important carrier of the world-class biopharmaceutical industry cluste.
It is reported that Li Zheng, secretary of the Fengxian District Party Committee, said at a seminar on the high-quality development of the biomedical industry in the Yangtze River Delta on August 11 that in recent years, Fengxian District has made every effort to launch the "Oriental Beauty Valley" brand and vigorously develop the beauty, health and biomedical industrie.
Up to now, Fengxian District has gathered more than 200 biopharmaceutical companies and introduced a number of functional platform.
Fengxian District will strive to become an important carrier for Shanghai to build a world-class biopharmaceutical industry cluste.
Hainan Hainan has always regarded the biopharmaceutical industry as one of the leading industries, and the "14th Five-Year Plan for the Development of High-tech Industries in Hainan Province" lists modern biopharmaceuticals as a strategic emerging industr.
It is worth mentioning that among them, Haikou has begun to build a 100 billion-level high-end pharmaceutical and medical device industry cluste.
At the same time, favorable policies are also being introduce.
On July 12, Haikou released the "Yecheng Talent Plan" focusing on key industries, including 35 measures such as full-cycle talent incentives and building a scientific research and innovation platform, to cultivate talents for industrial transformatio.
According to reports, in the next step, Haikou will introduce more flexible and precise support policies, build more platforms for cooperation and exchange, pay close attention to enterprise service guarantees, form an efficient and coordinated development of innovation chains and industrial chains, and support high-end, large-scale and intensive biopharmaceutical industrie.
developmen.
Shenzhen In recent years, Shenzhen has also highly supported the development of the biopharmaceutical industry, and favorable policies have continued this yea.
For example, in June, the "Shenzhen Action Plan for Cultivating and Developing Biomedical Industry Clusters (2022-2025)", "Shenzhen's Action Plan for Cultivating and Developing High-end Medical Device Industry Clusters (2022-2025)", "Shenzhen Cultivation and Development of High-end Medical Device Industry Clusters (2022-2025)" Health Industry Cluster Action Plan (2022-2025)" and other document.
In July, "Several Measures for Shenzhen to Promote the High-quality Development of Biomedical Industry Clusters", "Several Measures for Shenzhen to Promote the High-quality Development of High-end Medical Device Industry Clusters" and "Shenzhen's Measures for Promoting the High-quality Development of Big Health Industry Clusters" were successively release.
"Several Measures" and other policies to support Shenzhen to expand and strengthen the biomedical industr.
Conclusion Judging from the current intensive moves to support the high-quality and innovative development of the biopharmaceutical industry, the industry expects that the biopharmaceutical industry will enter the "fast lane" and will accelerate the realization of the "14th Five-Year Plan for the Development of the Biopharmaceutical Industry" It is proposed that by 2025, the operating income of the biopharmaceutical industry will reach 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth rate of more than 10.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
